Synthekine nabs megaround in bid to edge out Merck, Sanofi in IL-2 sprint
Nine months after launching out of Stanford with $82 million and a portfolio of engineered cytokines, Synthekine has landed a $107.5 million Series B …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
